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Summary The occurrence of bi-directional drug interactions between antiepileptic
drugs (AEDs) and combined oral contraceptives (OCs) pose potential risks of un-
intended pregnancy and as well as seizure deterioration.
It is well established that several of the older AEDs (carbamazepine, phenytoin and
phenobarbital), are strong inducers of the hepatic cytochrome P450 (CYP) 3A4
enzyme system, and are associated with increased the risk of contraceptive failure.
In addition, it is demonstrated that also some of the newer AEDs, oxcarbazepine and
topiramate influence on the pharmacokinetics of OCs, which is thought to be due to a
more selective induction of subgroups of the hepatic enzyme system.
Estrogens containing OCs induce the glucuronosyltransferase and may reduce the
plasma levels and the effect of AEDs cleared by glucuronidation. This has been most
intensively studied for lamotrigine but also other AEDs, which undergoes glucuronida-
tion processes, such as valproate and oxcarbazepine, may be affected by OCs.
Themagnitude of the drug—drug interactions show in general wide inter-individual
variability and the change in the elimination rate is often unpredictable and can be
influenced by a number of co-variants such as co-medication of other drugs, as well as
genetic and environmental factors. It is therefore recommended that change in OC
use is assisted by AED monitoring whenever possible.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Combined oral contraceptive steroids (OCs) are pre-
scribed for 17% of fertile women with epilepsy,
which is almost as frequent as for the background
population (25%).1 Co-administration of OCs and
antiepileptic drugs (AEDs) is therefore a common
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doi:10.1016/j.seizure.2007.11.012tions of possible drugs interactions. The main con-
sequences of these interactions are risks of un-
intended pregnancy or seizure deterioration. A con-
traceptive failure may be disastrous for all women
but is of specific clinical concern for women treated
with AEDs because of the teratogenetic potential of
the drugs. On the other end of the clinical spectrum
may recurrence of even a single seizure in a seizure-
free woman have detrimental psycho-social conse-
quences.
A surprising number of physicians do not have
adequate knowledge about potential interactions
between their AEDs and the OCs1 and approximately. Published by Elsevier Ltd. All rights reserved.
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they have never been given information about this
specific issue.2 A recent survey, however, has shown
that women with epilepsy of childbearing age do not
always recall being given information on contracep-
tion and pre-pregnant planning, which highlights
the need for regular repetitions.3
The objective of this paper was to review the
literature of the bi-directional interaction poten-
tials between AEDs and OCs and to discuss the gaps
of current knowledge in a future perspective.The effect of AEDs on the
pharmacokinetics of combined OCs
A drug interaction potential between AEDs and OCs
was suggested for the first time in the beginning of
the 1970s about 10 years after the introduction of
the combined OC. A higher incidence of break-
through bleeding and contraceptive failure among
women with epilepsy was observed and correlated
with the time when the ethinylestradiol fraction of
OCs was decreased from 50—100 to<50 mg to dimin-
ish the risk of thrombo-embolic side effects. The
contraceptive failure, therefore, was regarded as
mainly dependent on the concentration of the estro-
gen fraction of the OC.
Modern available combined OC preparations con-
tain 20—35 mg of ethinylestradiol and less than 1 mg
of progestogen. The major part of the estrogen com-
pound is hydroxylated to inactive metabolites by the
hepatic cytochrome P450 (CYP) 3A4 or directly con-
jugated. AEDs that induce the CYP 3A4 isoenzyme
(carbamazepine,4 felbamate,5 oxcarbazepine,6 phe-
nobarbital,7 phenytoin4 and topiramate)8may there-
fore accelerate the hepatic elimination of OCs. A
recent study of topiramate with an OC containing
35 mg ethinyl estradiol demonstrated that topira-
mate monotherapy in dose <200 mg did not signifi-
cantly affect the clinical efficacy of OCs.9
Theconsequences of thedrug interactionare a risk
of contraceptive failure and un-intended pregnancy.
Women who are prescribed drugs with a enzyme
inducing potential, have therefore been advised to
use high-dose OCs with a dose of the estrogen com-
pound of at least 50 mg (low-dose topiramate mono-
therapy 35 mg) and should be advised to use
additional barrier methods of contraception, espe-
cially in case of intramenstrual bleeding.
The extent of enzyme induction is correlated to
the dose of the drug but is difficult to quantify as
also genetic and environmental factors influence
the hepatic isoenzyme expression.10
Data available today suggest that neither of the
other newer AEDs; gabapentin,11 levetiracetam,12tiagabine,13 vigabatrin14 or zonisamide15 influence
the metabolism of OC and can be administrated
without risk of contraceptive failure. One study
has demonstrated a modest and probably not clin-
ical relevant decrease of the levonorgestrel com-
pound of the OCs during lamotrigine but no change
in the pharmacokinetic parameters of ethinylestra-
diol.16 This is in agreement with the former study by
Holdich et al.17 who found no effect of lamotrigine
on the elimination of OCs. Similarly, it has been
demonstrated that felbamate caused a 42%
decrease in gestogene AUC(0—24) but had no effect
on the metabolism of ethinylestradiol.5 These stu-
dies by Sidhu et al.16 and Saano et al.5 however,
were performed with a moderate dose of reproduc-
tive hormones, namely 35 mg ethinylestradiol and
150 ug levonorgestrel, and 75 mg gestogene, respec-
tively. In women who use low-dose OCs <30 mg and
<75 mg progesterone, ovulation might not be sup-
pressed. Midcycle bleeding should therefore always
alert the physician and the patient of the risk of
contraceptive failure.The effect of combined OCs on the
pharmacokinetics of AED´s
OCs can increase the metabolism of glucuronidated
drugs by induction of the uridine diphosphate glu-
curonosyltransferase system. This has been most
intensively studied for lamotrigine which is hepati-
cally metabolized primarily by glucuronic acid con-
jugation. Several studies have demonstrated that
lamotrigine is significantly and substantially (>50%)
increased by combined OCs16,19—21 and that this
interaction is associated with increased seizure fre-
quency in most of the cases.22
The contraceptive-induced pharmacokinetic
alteration shows a considerable inter-individual
variability based on probably both genetic factors
and co-administration with other AEDs. This can be
exemplified by the results in a recent study that
revealed that the OC induction of lamotrigine elim-
ination was almost eliminated when co-admini-
strated with valproate.23
The change in lamotrigine metabolism has
been attributed to the estrogen rather than the
progestin component of the OC19 and is most likely
caused by increased drug glucuronidation.21 The
lack of estrogens affects the pharmacokinetic
acutely and the plasma level of lamotrigine
increase in a fairly rapid and linear manner already
within the ‘‘pill-free’’ week.16,21,24 The clinical
consequences are not fully explored but because
of the rapid and significant increase of the plasma
levels the authors suggest that the up-titration of
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week’’ in order to avoid potential titration related
tolerability problems. In addition, standardization of
blood sampling in relation to the OC cycles is advi-
sable for lamotrigine therapeutic monitoring. Perso-
nal clinical experience shows that overdose
symptoms, in particular dizziness,may occur in single
patients during the pill-freeweek on high-dose lamo-
trigine (plasma concentrations>40 mmol/l) and that
a dose reduction of about 25% in theOC freeweek can
be successful.
Recent results suggest that also other AEDs,
eliminated fully or partly by glucuronidation, may
have a similar interaction with combined OCs. Based
on a single case Herzog et al. (2005) reported that
plasma concentrations of valproate fluctuated
widely during the OCs cycle.25 A subsequent paper
demonstrated that the plasma clearance of total
valproate increased with a mean of 21.5% during OC
intake period and of 45.2% for the unbound valpro-
ate fraction.26 The OC effect on valproate clearance
varied markedly across the subjects and may be of
significant clinical relevance in some patients. Also
the pharmacologically active monohydroxy derivate
of oxcarbazepine is mainly eliminated by glucuro-
nidation. The clinical relevance of this potential
effect of OC also needs to be further explored.
In most studies, OCs affection on AEDs elimina-
tion rate shows a great inter-individual variability.
The variability is probably multifactorial and
reflects differences in dosages of the AEDs, the
fraction cleared by conjugation, functional poly-
morphisms of glucuronosyltransferases and OC doses
and formulations. As the level of altered elimination
induced by OCs is unpredictable for the individual
patient, it is recommended that the plasma level of
all glucuronidated AEDs is carefully monitored and
doses adjusted before and after introduction or
discontinuation of OCs.Other contraceptives than OCs
Data on possible interactions between AEDs and pro-
gesterone-only pill’s, — injections and— implants are
very sparse.
One study demonstrated that the subdermal levo-
norgestrel implants have a high failure risk in women
receiving phenytoin.27 These contraceptives are
therefore generally regarded as less reliable and
should not be prescribed in women who are treated
with enzyme-inducing drugs.
The effect of intramuscular injection of 150 mg
medroxyprogesterone acetate seems to be unaf-
fected by enzyme inducing AEDs but the evidence
is very limited.28Intrauterine contraceptives may be an optimal
contraceptive choice for women treated with
enzyme inducing AEDs. The levonorgestrel-releasing
system delivers a local amount of hormone locally in
the uterus and systemic drug interaction potential is
low. However, one small study demonstrated that
the contraceptive failure of this intrauterine device
in 1.1% of women treated with AEDs compared to
0.2% in controls.29 Copper intrauterine devices have
a local spermicidal effect which is not regarded to
be affected by concomitant drugs.Perspectives
Although the potential of drug interactions between
OCs and AEDs have been recognized for many years,
there are still major gaps in the current knowledge
and further explorations are needed. First of all,
high-dose estrogen OCs may increase the risk of
thrombo-embolic diseases and well as breast cancer.
The extent of enzyme induction may be correlated
to the dose of the AEDs but it is difficult to quantify,
as genetic and environmental factors also affect
hepatic isoenzyme expression. Therefore, a quanti-
fication of the enzyme induction, based on indivi-
dual AEDs, dosages, genotypes for relevant drug
metabolizing enzymes and types of co-medication,
should be explored to avoid unnecessary high estro-
gen exposure. However, concerning the safety of the
OCs it has always been a mantra to focus on the
estrogen compound, as discussed further in this
issue it might be more relevant to ensure safe
contraception by adequate doses of the progestin
compounds. This also stresses the importance of
further explorations of the contraceptive safety
and possible interactions between AEDs and proges-
terone-only pills, injections and patches and
implants. Data available today suggest that the
newer generation of AEDs are less likely to interact
with OCs, but the enzyme inducing potential of all
the newer AEDs have not be fully explored. Similarly
there is an ongoing need to study the effects of OCs
the elimination of AEDs and/or their active meta-
bolites. This should especially be relevant for drugs
where the elimination involves glucuronidation pro-
cesses but also other elimination pathways may
affected.Conclusion
Treating women with epilepsy of fertile age includes
systematic, ongoing and accurate counseling on
optimal choice of contraception. The widely avail-
able range of AEDs stresses the importance of being
144 A. Sabersfamiliar with the various properties of the drugs and
to achieve a better understanding of the drug—drug
interactions and inter-individual variations. In case
of change in the use of OCs, drug monitoring is
recommended whenever possible. In future per-
spective there is an urgent need for prospective
and systematic studies of the interaction potential
on the pharmacokinetics of the different OCs and all
the newer AEDs. Charting pharmacogenetic factors
may be a valuable tool to provide an individualized
treatment strategy and refine the contraceptive
therapeutic planning to ensure the best possible
health for the women. Until then the intrauterine
contraceptives might be the first line contraceptive
method at least for women who receive enzyme
inducing AEDs.References
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